N-Acetyl Glutamine (Aceglutamide): A Comprehensive Reference
1. Identity and Chemical Characterization
1.1 Names and Synonyms
N-acetyl glutamine — more precisely N-acetyl-L-glutamine — is the acetylated derivative of the amino acid L-glutamine.
Its IUPAC name is N-acetylglutamine (or N²-acetylglutamine in systematic nomenclature), and its IUPAC systematic chemical name is (2S)-2-acetamido-5-amino-5-oxopentanoic acid.
Its International Nonproprietary Name (INN) is aceglutamide, and it is also encountered in the literature under the synonyms N²-acetyl-L-glutamine, acetyl-L-glutamine, Ac-L-Gln-OH, and L-glutamine, N-acetyl-.
It is important to distinguish N-acetyl glutamine from two related but distinct molecules:
- N-acetylglutamic acid (N-acetylglutamate; NAG) — the acetylated form of the amino acid glutamic acid (not glutamine), with the formula C₇H₁₁NO₅. This is a well-characterised metabolic intermediate in the urea cycle and arginine biosynthesis, and must not be conflated with N-acetyl glutamine.
- N-acetyl-D-glutamine — the D-enantiomer of N-acetyl glutamine, which is chemically identical in formula but mirror-image in configuration; its biological activity differs from the L-form.
1.2 Molecular Formula, CAS, and Physical Properties
N-Acetyl-L-glutamine has the molecular formula C₇H₁₂N₂O₄, a molecular weight of 188.18 g/mol, and is assigned CAS registry number 35305-74-9.
It is classified by ChEBI as "an N2-acetylglutamine that has L-configuration." The compound exists as a white to off-white crystalline powder that is soluble in water, a property that is central to its value in nutritional and pharmaceutical applications.
N-acetylglutamine, as a modified amino acid, offers greater chemical stability than glutamine under the conditions experienced during typical sterilization and shelf storage of liquid nutritionals.
Free glutamine is unstable in aqueous solution and can produce pyroglutamic acid, which is considered harmful to the human body.
Regardless of harsh conditions like sterilization or low pH, NAG shows better stability than glutamine, and it can be made into freeze-dried powder to further enhance its stability.
1.3 Stereochemistry and Enantiomers
A significant analytical challenge in working with aceglutamide is its existence as enantiomers — acetyl-L-glutamine and acetyl-D-glutamine — and stereoselective pharmacokinetics necessitates analytical methods that can separately quantify these isomers.
A chiral method was developed and validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to determine N-acetyl-glutamine enantiomers in biological samples.
Physiologically relevant supplemental and pharmaceutical preparations utilize the L-form, consistent with the natural stereochemistry of proteinogenic amino acids.
1.4 Decomposition Products
Under extreme degradation conditions (low pH, high temperature), the identified decomposition products of N-acetyl-L-glutamine include glutamine, glutamic acid, pyroglutamic acid, N-acetylglutamic acid, and a novel compound, N-(2,6-dioxo-3-piperidinyl) acetamide.
N-acetylglutamine (NAQ) is stable for six months at pH greater than 4.0 at approximately 20 °C. N-acetylglutamic acid, the major degradation product, was found in samples stored for two weeks or more, but remained at less than 1% through six months at pH 4.0 and higher.
No degradation of NAQ was observed in a liquid nutritional product at pH 6.5 after three months.
2. Endogenous Occurrence and Natural Sources
2.1 Endogenous Status in Humans
N-acetyl glutamine is catalogued in the Human Metabolome Database (HMDB) under accession number HMDB0006029 as a human metabolite. The enzyme aminoacylase-1 is involved in the hydrolysis of N-acylated or N-acetylated amino acids (except L-aspartate), making it the primary endogenous enzyme responsible for liberating free glutamine from the acetylated form.
Glutamine — the parent amino acid — accounts for approximately 60% of the total free amino acid pool in the human body and has functions in regulating the immune system and treating gastrointestinal disturbances.
Acetylglutamine (N-acetyl-L-glutamine, NAG) is a derivative of glutamine, produced by the acetylation of glutamine.
The acetylation reaction is analogous to the well-characterized biosynthesis of N-acetylglutamic acid from glutamic acid and acetyl-CoA, catalyzed by N-acetylglutamate synthase; however, N-acetyl glutamine (the amide form) is considered to have a different primary biosynthetic and metabolic context from N-acetylglutamic acid (the acid form).
2.2 Dietary and Food Sources
No peer-reviewed sources identified specific foods as particularly rich quantified sources of pre-formed N-acetyl glutamine in the human diet. The compound is not a major nutritional constituent tracked by food composition databases in the same way as free glutamine. Glutamine itself — the precursor — is found abundantly in animal proteins, particularly meat, poultry, fish, eggs, and dairy, as well as in certain plant foods. N-acetyl glutamine available for supplemental purposes is produced synthetically, typically by the chemical acetylation of L-glutamine derived from fermentation processes.
3. Traditional and Historical Use
N-acetyl glutamine is a synthetic or semi-synthetic derivative of a natural amino acid; it has no documented history of traditional use in herbal medicine, Ayurveda, Traditional Chinese Medicine (TCM), or other ethnomedicinal systems in its own right. It does not occur in any official traditional pharmacopoeia as an individual preparation. It was not isolated or characterised as a distinct pharmacological entity until the modern era of amino acid chemistry and clinical nutrition research, with its pharmaceutical and nutritional significance emerging primarily from research conducted from the 1980s onward.
In contemporary Chinese clinical medicine, aceglutamide (N-acetyl-L-glutamine) is a component of Guhong injection (GHI), a compound preparation composed of aceglutamide and an aqueous extract of safflower (Carthamus tinctorius L.). The combination of these two components is reported to have a synergistic effect on blood coagulation, causing anti-platelet aggregation, dilation of blood vessels, and anti-inflammatory effects. This represents the principal tradition in which the compound has been incorporated into a multi-ingredient preparation with a cultural context, but it is a modern pharmaceutical formulation rather than a historical folk remedy.
4. Key Constituents, Active Compound, and Mechanisms of Action
4.1 The Active Compound
N-acetyl glutamine is itself the active agent. Because it is a single, chemically defined molecule rather than a botanical extract, there is no complexity of multiple phytochemicals. Its pharmacological activity is understood to derive primarily from two interrelated sources: (1) its role as a prodrug or stable precursor that releases free L-glutamine upon enzymatic deacetylation, and (2) direct activities attributable to the intact aceglutamide molecule.
4.2 Prodrug / Glutamine-Precursor Mechanism
Aceglutamide functions as a prodrug to glutamine; once administered, it is hydrolyzed to release glutamine, which then participates in various metabolic pathways. Glutamine is a precursor to glutamate, an important neurotransmitter.
In pig studies, N-acetyl-L-glutamine (approximately 76%) was slightly less absorbed than free glutamine (approximately 85%) from the intestinal lumen into mucosa, where the intact aceglutamide molecule was not detected, suggesting almost complete hydrolysis during absorption.
This enzymatic deacetylation is catalysed by aminoacylase-1, which acts on N-acylated amino acids along the intestinal epithelium and in other tissues.
4.3 Blood-Brain Barrier Penetration
Aceglutamide has been described in pre-clinical research as a neuroprotectant that can penetrate the blood-brain barrier.
A pharmacokinetic study in rats demonstrated that NAG has easy and dose-dependent access to the blood-brain barrier and exhibits a medium retention time.
This property distinguishes it from free glutamine, whose passage across the blood-brain barrier is more tightly regulated, and may underlie its potential for neurological applications.
4.4 Antioxidant and Cytoprotective Mechanisms
Several pre-clinical (animal and cell-based) studies have explored the molecular mechanisms of aceglutamide. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx), and the transcription factor Nrf2. It also inhibits apoptosis signal-regulating kinase 1 (ASK1) and tumor necrosis factor receptor-associated factor 1 (TRAF1), activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes, and reduces oxidative damage.
In a rat model of cerebral ischemia-reperfusion, aceglutamide treatment improved behavioral functions, reduced infarction volume, and elevated the number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra. Aceglutamide significantly attenuated neuronal apoptosis in the substantia nigra, and significantly inhibited the expression of TRAF1 while up-regulating the expression of P-Akt and the Bcl-2/Bax ratio.
Blood-brain permeability studies indicated that GABA concentrations were notably elevated relative to glutamate in drug groups receiving NAG, suggesting that NAG and the GHI preparation increase the brain content of GABA to counteract excessive glutamate and maintain the balance of brain function.
4.5 Stability and Glutamine Pool Replenishment
A core rationale for N-acetyl glutamine in clinical nutrition is that the acetyl group confers aqueous and thermal stability, permitting the compound to survive sterilization and storage conditions that degrade free glutamine, while the body can subsequently hydrolyze it back to usable glutamine.
Animal studies adding NAG to parenteral nutrition solutions indicated that NAG was efficiently utilized to synthesize protein and hence may serve as a precursor for glutamine.
The plasma level of glutamine was reported to double in dogs injected with NAG intravenously.
5. Scientific Evidence by Area of Use
5.1 Parenteral and Clinical Nutrition
Background and Rationale
L-glutamine is too unstable for inclusion in solutions for parenteral nutrition, but its acetylated analogue, N-acetyl-L-glutamine, is not.
Although considered a non-essential amino acid, glutamine becomes essential in clinical conditions associated with protein catabolism such as surgical stress: the striking depletion of muscle glutamine observed in these situations can be prevented by glutamine administration but not by classical nutrition regimens that are devoid of glutamine. Glutamine also stimulates sodium absorption and may have a trophic effect on small intestinal mucosa.
Human Pharmacokinetic and Utilization Studies
A three-part human study investigated the utilization of intravenously administered acetylglutamine. In study 1, nine healthy post-absorptive subjects were given 9.4 g of acetylglutamine IV during four hours.
In study 2, five healthy subjects were studied on two occasions following an overnight fast; they were given 9.4 g of acetylglutamine or an equivalent amount of glutamine as part of a total parenteral nutrition (TPN) regimen during 7.2 hours.
In study 3, four patients were studied the day after major surgery; they were given the same TPN regimen containing 9.4 g of acetylglutamine during 7.2 hours.
Key findings from this landmark 1989 pharmacokinetic study were as follows:
- In study 1, the plasma concentration of glutamine rose from 594 ± 28 μmol/L to 728 ± 26 μmol/L (P < .001), whereas plasma levels of acetylglutamine exceeded 1,000 μmol/L in all subjects at the end of infusion.
- The eight-hour urinary excretion of acetylglutamine and glutamine corresponded to 18% of the infused amount of acetylglutamine. No net exchange of acetylglutamine across the splanchnic tissues could be determined, but the kidneys extracted acetylglutamine (165 ± 54 μmol/min) and there was a glutamine release (90 ± 10 μmol/min), indicating renal deacetylation.
- In study 2, glutamine concentration rose from 537 ± 42 μmol/L to 726 ± 51 μmol/L (P < .001) when acetylglutamine was infused, comparable to the rise observed with direct glutamine administration. No significant increase in glutamine concentration was found in the control study (no glutamine or aceglutamide).
- Urinary excretion of acetylglutamine and glutamine over 24 hours corresponded to 34% of the administered acetylglutamine dose.
- In study 3 (post-surgical patients), glutamine concentration was 422 ± 33 μmol/L before infusion; acetylglutamine concentration rose from undetectable values to 517 ± 84 μmol/L. Urinary excretion during 24 hours corresponded to 41% of the infused amount.
Well tolerance and no obvious side effects were found in healthy volunteers and postoperative patients intravenously injected with NAG (as reported by Magnusson et al., 1989).
Evidence assessment: The 1989 human study (Magnusson et al., published in Metabolism) provides direct human pharmacokinetic evidence that IV aceglutamide is converted to free glutamine and raises circulating glutamine levels in both healthy volunteers and post-surgical patients. Sample sizes are small (4–9 subjects), and this work primarily establishes proof-of-concept rather than clinical efficacy outcomes (e.g., mortality, morbidity, or length of stay). It has not been superseded by large randomized controlled trials specifically testing N-acetyl-L-glutamine as the glutamine source in parenteral nutrition; most subsequent parenteral glutamine research instead employed the dipeptide alanyl-glutamine (Ala-Gln).
Comparison with Other Glutamine Delivery Vehicles
In vivo studies in humans and animals provide firm evidence that the synthetic glutamine-containing dipeptide L-alanyl-L-glutamine (Ala-Gln) is readily hydrolyzed following intravenous administration, and its use as a source of free glutamine in parenteral nutrition is considered safe and efficient. In clinical studies, nitrogen balance was more positive in catabolic patients receiving a peptide-supplemented solution than in control patients given isonitrogenous, isoenergetic total parenteral nutrition.
The dipeptide Ala-Gln, rather than N-acetyl-L-glutamine, became the dominant pharmaceutical glutamine source in IV nutrition, in part because of concerns about the higher urinary loss of intact aceglutamide and the comparatively incomplete conversion demonstrated in post-surgical patients. Industry patent literature also noted that N-acetyl-L-glutamine is, if at all, only a very poor glutamine source for cells in tissue culture media, whereas N-acetyl-L-alanyl-L-glutamine dipeptides proved more effective.
5.2 Enteral Nutrition — Intestinal Absorption and Gut Health
The instability of glutamine in liquid media has prompted evaluation of reasonable enteral nutrition sources of glutamine; N-acetyl-L-glutamine offers no instability and no intolerance problems, and was studied for its absorption and apparent digestibility compared to free glutamine.
Based on pig model studies, N-acetyl-L-glutamine appeared to be a good candidate for glutamine fortification of enteral nutrition formulas.
A published animal study (ResearchGate/Journal of Nutrition, 2007) investigated whether N-acetyl-L-glutamine could partially prevent the effects of protein-energy malnutrition on body weight and intestinal immunity in pigs. N-acetyl-L-glutamine (approximately 76%) was slightly less absorbed than glutamine (approximately 85%) from the intestinal lumen into mucosa, where it was not detected as an intact molecule, suggesting almost complete hydrolysis during absorption. The study reported partial prevention of intestinal immune changes associated with protein-energy malnutrition, positioning NAQ as a liquid-stable source of glutamine with potential to protect mucosal immunity.
Evidence assessment: Intestinal evidence is largely from pig (porcine) models, which are anatomically and physiologically similar to humans in digestive terms. Direct human clinical trials specifically evaluating enteral N-acetyl glutamine on gut mucosal outcomes are sparse in the available literature. The evidence is preliminary, and translation to confirmed clinical benefit in human enteral nutrition has not been established by randomized controlled trials.
5.3 Neuroprotection and Neurological Applications
The most active area of aceglutamide research in recent years has been in pre-clinical models of neurological injury, particularly ischemic stroke.
Pre-clinical Evidence (Animal and Cell-Based Studies)
In adult male Sprague-Dawley rats subjected to two hours of transient middle cerebral artery occlusion (MCAO) as a model of ischemia-reperfusion injury, aceglutamide or vehicle was given intraperitoneally beginning 24 hours after reperfusion and continuing for 14 days, after which functional recovery was assessed and the number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra was analyzed.
Aceglutamide treatment improved behavioral functions, reduced infarction volume, elevated the number of TH-positive neurons in the substantia nigra, and significantly attenuated neuronal apoptosis. Aceglutamide significantly inhibited the expression of TRAF1 and up-regulated the expression of P-Akt and the Bcl-2/Bax ratio, both in vitro and in vivo. The conclusions were that aceglutamide ameliorated motor dysfunction and delayed neuronal death in the substantia nigra after ischemia, involving inhibition of the pro-apoptotic factor TRAF1 and activation of the Akt/Bcl-2 signaling pathway.
Guhong injection (GHI), a compound preparation of Chinese and Western medicine, is composed of safflower water extract and aceglutamide, and has demonstrated therapeutic effects on cerebral ischemia diseases in pre-clinical research.
Hydroxysafflor yellow A in combination with aceglutamide was found to have a synergistic neuroprotective action against ischemic stroke via restraint of inflammatory and apoptotic mechanisms.
Aceglutamide, a glutamine acetyl derivative, is described as a liquid-stable source of glutamine, with the same pharmacological effect as glutamine; it has been reported to significantly improve the clinical prognosis of patients who had a stroke in one referenced clinical source (Wasa et al., 2005).
Pharmacokinetics in the Central Nervous System
A study on acetylglutamine pharmacokinetics in rat blood and brain used liquid chromatography-tandem mass spectrometry (LC-MS/MS) and microdialysis to evaluate NAG and its metabolites γ-aminobutyric acid (GABA) and glutamic acid in rat blood and brain.
The study demonstrated that NAG has easy and dose-dependent access to the blood-brain barrier and exhibits a medium retention time.
The blood-brain permeability of GABA was markedly increased compared with glutamate in drug groups, indicating that NAG and GHI increase the brain content of GABA to counteract excessive glutamate and maintain the balance of brain function.
Evidence Assessment for Neuroprotection
The neuroprotection evidence for aceglutamide is currently limited to animal models (primarily rat MCAO models) and in vitro cell studies. The compound appears active in these systems via anti-apoptotic and antioxidant mechanisms. However, no large, well-controlled human randomized clinical trials specifically examining N-acetyl glutamine monotherapy in stroke or other neurological conditions were identified in the peer-reviewed literature accessible for this review. The use of aceglutamide as part of Guhong injection in China represents clinical practice, but robust Phase III RCT evidence specific to aceglutamide as an individual agent in humans is lacking. The gap between pre-clinical promise and human clinical validation is a well-documented challenge in neuroprotective pharmacology generally.
5.4 Critical Illness and Surgical Stress
The concept that glutamine becomes a "conditionally essential" amino acid under surgical and critical illness stress has been well established in the broader glutamine literature. Glutamine becomes essential in clinical conditions associated with protein catabolism such as surgical stress; the striking depletion of muscle glutamine observed in these situations can be prevented by glutamine administration but not by classical nutrition regimens that are devoid of glutamine.
N-acetyl glutamine was investigated as a vehicle for providing this supplemental glutamine parenterally, as noted in the Magnusson et al. pharmacokinetic studies. The post-surgical patient arm of that study showed that aceglutamide infusion resulted in measurable rises in plasma glutamine, though the magnitude of the increase was smaller than in healthy volunteers, likely reflecting the accelerated glutamine consumption under surgical stress.
In clinical guidelines referenced in the literature, glutamine for parenteral nutrition in critically ill patients was administered exclusively via the parenteral route, using approved and recommended doses of 0.3–0.5 g/kg body weight per day, in combination with adequate nutrition in patients who were hemodynamically and metabolically stabilized, excluding patients with hepatic and/or renal failure. These guidelines generally pertain to glutamine sources (often alanyl-glutamine dipeptide) rather than N-acetyl glutamine specifically.
5.5 Metabolomics and Biomarker Research
N-acetyl glutamine has been identified as a measurable metabolite in human biofluids through metabolomics investigations. It appears in blood and urine metabolome profiling studies, where it serves as an endogenous biomarker of glutamine metabolism status. Its measurement is used in metabolomic studies examining nitrogen metabolism, amino acid turnover, and conditions involving altered glutamine homeostasis, such as critical illness, malnutrition, and disease states affecting the liver, kidney, and gut.
6. Body Systems and Health Areas of Association
- Gastrointestinal system: As a stable glutamine precursor, N-acetyl glutamine is associated with support of intestinal mucosal integrity, enterocyte energy supply (glutamine is a primary fuel for rapidly dividing intestinal cells), and maintenance of gut-associated lymphoid tissue (GALT) function.
- Immune system: Glutamine released from aceglutamide supports lymphocyte and macrophage proliferation; glutamine depletion under catabolic stress is associated with immune compromise, and supplementation has been studied for its effects on mucosal immunity.
- Central nervous system: Aceglutamide crosses the blood-brain barrier, and pre-clinical evidence associates it with neuroprotection, modulation of the glutamate/GABA balance, and anti-apoptotic signaling in neurons.
- Nitrogen metabolism and protein synthesis: As a glutamine source, N-acetyl glutamine contributes to nitrogen transport between organs, nucleotide biosynthesis, and protein anabolism, particularly relevant in catabolic states.
- Kidney: The kidneys play a specific role in deacetylating aceglutamide to release free glutamine, with kidneys extracting aceglutamide at 165 ± 54 μmol/min and releasing glutamine at 90 ± 10 μmol/min. A proportion of administered aceglutamide is excreted intact in urine, which represents a relevant route of loss.
- Oxidative stress and antioxidant systems: Pre-clinical studies associate aceglutamide with activation of the GSH, Trx, and Nrf2 antioxidant pathways.
7. Dosage Forms and Doses Reported in Research
7.1 Pharmaceutical and Supplement Forms
N-acetyl glutamine is available in or has been studied in the following forms:
- Intravenous solution: Used in clinical nutrition and pharmacokinetic research, typically dissolved in sterile water or amino acid solutions for IV infusion.
- Oral powder / capsule / tablet: Used in dietary supplement contexts for enteral delivery.
- Freeze-dried powder: NAG can be made into freeze-dried powder to enhance its stability, particularly where liquid formulations are impractical.
- Liquid nutritional products: Incorporated as a glutamine substitute in liquid enteral nutrition formulas, where its stability advantage over free glutamine is most significant.
- Injectable preparation (Guhong injection): The concentration of aceglutamide in Guhong injection is 30 mg/ml, and the commonly used clinical dose is 10–20 ml through intravenous injection.
7.2 Doses Reported in Specific Studies
- Healthy volunteers, IV (Magnusson et al., 1989 — Study 1):
Nine healthy post-absorptive subjects were given 9.4 g acetylglutamine IV during four hours.
- Healthy volunteers, IV as part of TPN (Magnusson et al., 1989 — Study 2):
Five healthy subjects were given 9.4 g of acetylglutamine or an equivalent amount of free glutamine as part of a TPN regimen during 7.2 hours.
- Post-surgical patients, IV as part of TPN (Magnusson et al., 1989 — Study 3):
Four patients, studied the day after major surgery, were given the same TPN regimen containing 9.4 g acetylglutamine during 7.2 hours.
- Guhong injection (clinical use in China):
The aceglutamide concentration in Guhong injection is 30 mg/ml, with a commonly used clinical dose of 10–20 ml by intravenous injection.
- Parenteral nutrition guidelines (general glutamine, not specific to aceglutamide):
Guidelines recommend 0.3–0.5 g/kg body weight per day via the parenteral route for critically ill patients. This pertains to glutamine supplementation broadly and is not specific to N-acetyl glutamine as the delivery form.
No standardized supplemental dose for oral N-acetyl glutamine has been established in peer-reviewed literature. Supplement-industry dosing recommendations are not referenced here as they do not constitute verified scientific evidence.
8. Safety Considerations and Known Interactions
8.1 Tolerability in Human Studies
Well tolerance and no obvious side effects were found in healthy volunteers and postoperative patients intravenously injected with NAG in the Magnusson et al. (1989) study.
The available human data, though small in scale, did not identify significant adverse events at the doses studied (9.4 g IV over 4–7.2 hours).
8.2 Urinary Loss as an Efficiency Consideration
A relevant safety-adjacent pharmacokinetic issue is the substantial urinary excretion of intact aceglutamide. Urinary excretion of aceglutamine and glutamine over 24 hours corresponded to 34% of the administered aceglutamide dose under TPN conditions in healthy subjects.
In post-surgical patients, urinary excretion during 24 hours corresponded to 41% of the infused amount.
This high renal clearance of intact aceglutamide means a substantial fraction of a dose is lost before deacetylation occurs, particularly under conditions of surgical stress, limiting its efficiency as a parenteral glutamine delivery vehicle compared to alternatives such as alanyl-glutamine.
8.3 Decomposition Products at Low pH
At pH 2.0 and 3.0, N-(2,6-dioxo-3-piperidinyl) acetamide — a novel decomposition compound — is detected; pyroglutamic acid also forms at pH ≤ 3.0. These degradation products are formed only under atypically acidic conditions not representative of standard formulation. Free glutamine is itself unstable in aqueous solution and can produce pyroglutamic acid, which is considered harmful to the human body; the acetylated form substantially reduces but does not entirely eliminate this risk under extreme conditions.
8.4 Contraindications Inferred from Related Glutamine Literature
The broader clinical glutamine literature provides context for populations in whom glutamine supplementation (and therefore aceglutamide as a glutamine source) has been associated with concern. Parenteral glutamine supplementation, per clinical guidelines, excludes patients with hepatic and/or renal failure, as these organs are central to the metabolism and excretion of glutamine and its derivatives. Given that aceglutamide is substantially processed by the kidneys (renal deacetylation and urinary excretion), renal impairment is a particularly relevant consideration when using this compound parenterally.
8.5 Absence of Interaction Data
No specific drug-drug interaction data for N-acetyl-L-glutamine as a dietary supplement were identified in the peer-reviewed literature reviewed for this article. A primary mechanism for drug-drug interactions with compounds sharing a structural relationship to antacids involves alterations in gastric pH and the formation of insoluble chelation complexes with other drugs, which can significantly reduce their absorption and bioavailability; however, this was noted in the context of aceglutamide aluminum (an aluminum-chelated form used as an antacid in some markets) rather than the standard aceglutamide itself, and these findings are not confirmed in clinical settings for the standard L-form.
8.6 Evidence Gaps
Formal safety data — including systematic toxicology assessments, dose-escalation studies, chronic dosing tolerability studies, and dedicated adverse event reporting — specific to oral N-acetyl glutamine as a dietary supplement are not present in the peer-reviewed literature identified by this review. Long-term safety, reproductive toxicity, and pediatric safety data are similarly absent from the available literature at this standard of evidence.
9. Summary of Evidence Quality
The overall evidence base for N-acetyl glutamine as a nutritional supplement or pharmaceutical agent can be characterized as follows:
- Strongly established: Chemical identity, aqueous and thermal stability advantage over free glutamine, mechanism of enzymatic deacetylation via aminoacylase-1, and blood-brain barrier penetration in animal models.
- Established (human data, small scale): IV pharmacokinetics in healthy volunteers and post-surgical patients; demonstration that IV aceglutamide raises plasma glutamine concentrations; acceptable tolerability at studied doses.
- Preliminary (animal/in vitro only): Neuroprotective effects in ischemia-reperfusion models; anti-apoptotic and antioxidant mechanisms (TRAF1 inhibition, Akt/Bcl-2 activation, Nrf2 enhancement); GABA/glutamate balance modulation in the brain.
- Insufficient evidence (human RCTs lacking): Enteral supplementation outcomes in humans; neuroprotection in human stroke; clinical outcomes in critical illness specific to this compound rather than to glutamine supplementation generally.
References
Go back